Psoriasis treatment study for healthy participants
Part of Skin clinical trials.
This study tests a new oral medication for psoriasis in healthy volunteers to check its safety and how the body handles it. It is an early-phase trial to gather information before testing in patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 55 years old
- Be in good overall health
- Have a body mass index (BMI) between 18 and 36
- Not have any major medical conditions like heart, liver, or kidney disease
- Not have a history of cancer or severe allergies
- Have no active infections like hepatitis B, hepatitis C, tuberculosis, or HIV
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new oral medication (HS-20118) for safety and how it works in the body. It is for healthy volunteers or people with chronic plaque psoriasis, and will help see if the drug is safe and how it behaves with or without food.
This trial tests a new study drug called HSK44459 for people with moderate to severe plaque psoriasis. The hope is that the drug can reduce psoriasis symptoms and improve quality of life. Participation involves receiving the study drug and being monitored for safety and effectiveness.
This study tests a new medicine called HS-20118 in two parts: one in healthy adults to see how the body handles a single dose, and another in people with chronic plaque psoriasis to see how it works over multiple doses. It helps find a safe dose and shows whether it might reduce psoriasis symptoms.
This trial tests a new medication (HS-10374) taken by mouth to see if it is safe and effective for people with moderate to severe plaque psoriasis. It might help reduce the redness, scaling, and thickness of psoriasis plaques.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
This Phase 1 study tests a new drug (SFA002) in adults with stable plaque psoriasis. It mainly focuses on safety and how the body responds, and may eventually help people with psoriasis plaques.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.